Invivyd Announces Progress In REVOLUTION Clinical Program For VYD2311, Monoclonal Antibody Investigational Candidate For Prevention Of Symptomatic COVID-19

Benzinga Newsdesk www.benzinga.com Positive 93.0%

Neg 0% Neu 0% Pos 93%

Comments

No comments yet. Be the first!